Immunome, Inc.
General ticker "IMNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Immunome, Inc. follows the US Stock Market performance with the rate: 47.1%.
Estimated limits based on current volatility of 2.5%: low 26.73$, high 28.12$
Factors to consider:
- Total employees count: 177 (+50.0%) as of 2025
- Top business risk factors: History of losses, Limited operating history, Capital raising failure, Regulatory and compliance, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.51$, 29.78$]
- 2026-12-31 to 2027-12-31 estimated range: [7.72$, 21.10$]
Financial Metrics affecting the IMNM estimates:
- Negative: with PPE of -9.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -10.06 <= 0.28
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 92.85 > 63.63
Short-term IMNM quotes
Long-term IMNM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $14.02MM | $9.04MM | $6.94MM |
| Operating Expenses | $123.55MM | $314.84MM | $231.05MM |
| Operating Income | $-109.53MM | $-305.80MM | $-224.11MM |
| Non-Operating Income | $2.72MM | $12.84MM | $11.72MM |
| R&D Expense | $103.89MM | $281.89MM | $187.29MM |
| Income(Loss) | $-106.81MM | $-292.96MM | $-212.39MM |
| Net Income(Loss)* | $-106.81MM | $-292.96MM | $-212.39MM |
| Stockholders Equity | $119.88MM | $181.16MM | $634.34MM |
| Assets | $148.54MM | $240.24MM | $683.19MM |
| Operating Cash Flow | $-7.57MM | $-110.79MM | $-190.92MM |
| Capital expenditure | $0.83MM | $53.51MM | $9.69MM |
| Investing Cash Flow | $-30.48MM | $-85.06MM | $60.80MM |
| Financing Cash Flow | $116.41MM | $240.53MM | $640.36MM |
| Earnings Per Share** | $-5.38 | $-5.00 | $-2.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.